Citigroup Initiates Coverage On Dianthus Therapeutics with Buy Rating, Announces Price Target of $156
Benzinga Newsdesk 1 month ago
NewsInitiationAnalyst RatingsPrice Target
Citigroup analyst Samantha Semenkow initiates coverage on Dianthus Therapeutics (NASDAQ:DNTH) with a Buy rating and announces Price Target of $156.
Citigroup analyst Samantha Semenkow initiates coverage on Dianthus Therapeutics (NASDAQ:DNTH) with a Buy rating and announces Price Target of $156.